SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-077700
Filing Date
2021-06-07
Accepted
2021-06-07 16:30:35
Documents
5
Period of Report
2021-07-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2117172-2_def14a.htm DEF 14A 633855
2 GRAPHIC lg_vynethera-4c.jpg GRAPHIC 481141
3 GRAPHIC sg_daviddomzalski-bw.jpg GRAPHIC 6648
4 GRAPHIC tm2117172d2-px_annualbw.jpg GRAPHIC 656427
5 GRAPHIC tm2117172d2-px_signedbw.jpg GRAPHIC 886734
  Complete submission text file 0001104659-21-077700.txt   3421496
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38356 | Film No.: 21999888
SIC: 2834 Pharmaceutical Preparations